Hyperfine (HYPR) Capital Expenditures Growth (3y) (2024 - 2026)
Hyperfine (HYPR) Capital Expenditures Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.26 Bn | 175.96 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 128.79 Bn | 125.92 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 108.56 Bn | 99.34 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 68.31 Bn | 66.86 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 47.27 Bn | 43.60 Bn | 1.29 Bn | 1.81% |
| 6 | Dexcom | 28.42 Bn | 27.31 Bn | 750.30 Mn | 0.84% |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.12 Bn | 1.98 Bn | 7.57% |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.40 Bn | 2.07 Bn | 2.15% |
| 10 | Hyperfine | 93.72 Mn | 52.44 Mn | 1.98 Mn | 24.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.22% |
| Dec 31, 2025 | -32.52% |
| Sep 30, 2025 | -35.26% |
| Jun 30, 2025 | 127.82% |
| Mar 31, 2025 | -59.59% |
| Dec 31, 2024 | -52.21% |
| Sep 30, 2024 | -31.54% |
| Jun 30, 2024 | 43.10% |
| Mar 31, 2024 | 133.88% |